CRSP CRISPR Therapeutics AG - Common Shares
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 3, 2026
$55,43
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$44,1252tyg. minimum
$78,4852tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
Przychody (TTM)
$13M
Twoje odznaki
Zakres 52 tyg.
$44–$78
Ocena Analityków
BUY
Cena Docelowa
$88
P/E
-11.8
ROE
-26.1%
Marża Zysku Netto
-3368.7%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
CRSP Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$55.43
Kapitalizacja Rynkowa (MRQ)
$5.36B
P/E (TTM)
-11.8
EPS (TTM)
$-4.71
Przychody (TTM)
$13M
ROE (TTM)
-26.1%
Zakres 52 tyg.
$44–$78
CRSP Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O CRISPR Therapeutics AG - Common Shares Przegląd firmy z Wikipedii
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaBiotechnology
krajCH
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$4M2016-12-31 → 2025-12-31
EPS$-6.472017-12-31 → 2025-12-31
Wolny przepływ pieniężny$-346M2016-12-31 → 2025-12-31
Marża netto-3368.7%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | CRSP | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -11.8średnia z 5 lat ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 400.1średnia z 5 lat ≈841.4 | ≈841.4 | · | · | |
| P/B (MRQ) | 3.1średnia z 5 lat ≈2.2 | ≈2.2 | · | · | |
| Cena / FCF (TTM) | -14.4średnia z 5 lat ≈-9.9 | ≈-9.9 | · | · | |
| Cena / Przepływy pieniężne (TTM) | -14.5średnia z 5 lat ≈-10.6 | ≈-10.6 | · | · | |
| Price / Tangible Book (Cena / Wartość księgowa materialna) | 2.8średnia z 5 lat ≈2.2 | ≈2.2 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | CRSP | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | -3990.0%średnia z 5 lat ≈-15278.7% | ≈-15278.7% | · | · | |
| Marża EBITDA (TTM) | -3850.4%średnia z 5 lat ≈-14752.4% | ≈-14752.4% | · | · | |
| Marża przed opodatkowaniem (TTM) | -3346.1%średnia z 5 lat ≈-14347.2% | ≈-14347.2% | · | · | |
| Marża Zysku Netto (TTM) | -3368.7%średnia z 5 lat ≈-14364.6% | ≈-14364.6% | · | · | |
| ROA (TTM) | -19.3%średnia z 5 lat ≈-11.7% | ≈-11.7% | -40.4% | Najwyższa półka | |
| ROE (TTM) | -26.1%średnia z 5 lat ≈-15.6% | ≈-15.6% | -46.3% | Najwyższa półka | |
| ROIC | -34.8%średnia z 5 lat ≈-18.3% | ≈-18.3% | -57.7% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | CRSP | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Wskaźnik bieżący (MRQ) | 17.8średnia z 5 lat ≈17.7 | ≈17.7 | 7.8 | Silna płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 13.2średnia z 5 lat ≈17.5 | ≈17.5 | 6.5 | Silna płynność |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | CRSP | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | -90.6%średnia z 5 lat ≈31552.0% | ≈31552.0% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 43.1%średnia z 5 lat ≈226.6% | ≈226.6% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 37.3% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | CRSP | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.0średnia z 5 lat ≈0.1 | ≈0.1 | · | · | |
| Receivables Turnover (Rotacja należności) | 0.3średnia z 5 lat ≈817.5 | ≈817.5 | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.09%
Następny raport
Lis 09, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 10, 2026 | $-0.94 | $-1.22 | 23.0% |
| 31 marca 2026 | $-1.28 | $-1.25 | -2.5% | |
| 31 grudnia 2025 | $-1.37 | $-1.18 | -16.4% | |
| 30 września 2025 | $-1.17 | $-1.29 | 9.0% | |
| 30 czerwca 2025 | $-1.29 | $-1.45 | 11.2% | |
| 31 marca 2025 | $-1.58 | $-1.28 | -23.9% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $20.04 | $22.53 | $23.52 | $23.89 | $31.17 | $22.52 | $15.46 | $7.56 | $4.63 | $5.86 | · | |
| Revenue / Share | $0.04 | $0.44 | $4.69 | $0.02 | $11.38 | $0.01 | $5.09 | · | · | · | · | |
| Cash Flow / Share | $-3.84 | $-1.69 | $-3.29 | $-6.38 | $6.70 | $-3.61 | $1.00 | · | · | · | · | |
| Cash / Share | $3.62 | $3.48 | $4.87 | $2.70 | $11.99 | $15.81 | $15.53 | $8.81 | $5.91 | $7.94 | · | |
| EPS (TTM) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-7.05 | · |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | · | 91,305,337 | 87,069,690 | 85,938,720 | · | 85,234,926 | 84,920,929 | 81,794,630 | · | 79,414,098 | 79,091,061 | 78,676,986 | · | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $18.07 | $18.83 | · | $20.41 | $19.36 | $21.18 | · | $22.73 | $23.29 | $24.56 | · | $21.75 | $22.88 | $23.52 | · | $24.97 | |
| Revenue / Share | $0.11 | $0.02 | · | $0.01 | $0.01 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.00 | $0.89 | $1.27 | · | $0.00 | |
| Cash Flow / Share | · | $-1.13 | · | · | · | $-0.63 | · | · | · | $1.34 | · | · | · | $0.11 | · | · | |
| Cash / Share | $3.01 | $4.39 | · | $3.05 | $2.19 | $2.72 | · | $2.64 | $5.70 | $8.34 | · | $6.64 | $5.60 | $4.37 | · | $6.32 | |
| EPS (TTM) | $-4.71 | $-6.17 | · | $-5.56 | $-5.40 | $-4.49 | · | $-2.81 | $-3.21 | $-2.70 | · | $-4.46 | $-5.29 | $-6.71 | · | $-8.52 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $38M | $38M | $38M | · | $203M | $202M | $272M | · | $170M | $170M | $100M | · | $14M | |
| Net Income TTM | $-451M | $-569M | · | $-488M | $-468M | $-386M | · | $-240M | $-266M | $-217M | · | $-354M | $-416M | $-524M | · | $-681M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -11.6 | -7.7 | · | -11.7 | -9.0 | -7.6 | · | -16.7 | -16.8 | -25.2 | · | -10.2 | -10.6 | -6.7 | · | -7.7 | |
| P/S | 393.7 | 1117.5 | · | 158.7 | 113.0 | 78.0 | · | 19.8 | 22.7 | 21.3 | · | 21.2 | 26.2 | 35.6 | · | 362.9 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| Earnings Yield | -8.6% | -13.0% | · | -8.6% | -11.1% | -13.2% | · | -6.0% | -5.9% | -4.0% | · | -9.8% | -9.4% | -14.8% | · | -13.0% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $4M | $37M | $371M | $1M | $915M |
| Marża Operacyjna % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Zysk netto | $-582M | $-366M | $-154M | $-650M | $378M |
| Rozwodniony EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Wskaźnik Szybkości | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-346M | $-145M | $-270M | $-533M | $457M |
Właściciele instytucjonalni (13F) 572 emitenci · $4.3B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
572
Wartość posiadanych akcji
$4.3B
Nowe pozycje
82
Zamknięte pozycje
47
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 82 (-14 vs poprzedni kw.) | 47 (-13 vs poprzedni kw.) | 158 (-19 vs poprzedni kw.) | 157 (+29 vs poprzedni kw.) | -2.0M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| ARK Investment Management LLC | $515 999 631 | 9 460 939 | 12,01% | Akcje |
| BlackRock, Inc. | $455 353 197 | 8 348 977 | 10,60% | Akcje |
| Orbis Allan Gray Ltd | $297 197 241 | 5 449 161 | 6,92% | Akcje |
| Capital World Investors | $259 039 094 | 4 749 525 | 6,03% | Akcje |
| STATE STREET CORP | $235 703 664 | 4 321 666 | 5,49% | Akcje |
| GSK plc | $175 652 997 | 3 220 627 | 4,09% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $136 919 043 | 2 509 915 | 3,19% | Akcje |
| VANGUARD GROUP INC | $118 954 581 | 2 268 394 | 2,77% | Akcje |
| SR One Capital Management, LP | $111 194 134 | 2 038 763 | 2,59% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $108 459 389 | 1 988 621 | 2,53% | Akcje |
| FMR LLC | $104 089 735 | 1 908 503 | 2,42% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $93 848 832 | 1 720 734 | 2,19% | Akcje |
| Amova Asset Management Americas, Inc. | $93 762 487 | 1 720 097 | 2,18% | Akcje |
| EcoR1 Capital, LLC | $75 771 113 | 1 389 276 | 1,76% | Akcje |
| UBS Group AG | $71 856 395 | 1 317 499 | 1,67% | Akcje |
| Capital International Investors | $69 178 918 | 1 268 407 | 1,61% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $64 457 935 | 1 181 847 | 1,50% | Akcje |
| BANK OF AMERICA CORP /DE/ | $62 999 405 | 1 155 105 | 1,47% | Akcje |
| NEA Management Company, LLC | $57 734 408 | 1 058 570 | 1,34% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57 694 430 | 1 057 837 | 1,34% | Akcje |
| D. E. Shaw & Co., Inc. | $48 748 506 | 893 812 | 1,13% | Akcje |
| MORGAN STANLEY | $47 992 455 | 879 949 | 1,12% | Akcje |
| NORTHERN TRUST CORP | $47 072 983 | 863 091 | 1,10% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35 380 807 | 648 713 | 0,82% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $31 089 982 | 570 040 | 0,72% | Akcje |
| CITADEL ADVISORS LLC | $25 404 514 | 465 796 | 0,59% | Akcje |
| JPMORGAN CHASE & CO | $24 569 275 | 431 669 | 0,57% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 298 288 | 427 178 | 0,54% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $20 836 025 | 382 032 | 0,49% | Akcje |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20 833 789 | 381 991 | 0,49% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18 456 336 | 338 400 | 0,43% | Opcja sprzedaży |
| Bank of New York Mellon Corp | $17 821 531 | 326 761 | 0,41% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17 763 678 | 325 700 | 0,41% | Opcja kupna |
| Logos Global Management LP | $16 362 000 | 300 000 | 0,38% | Akcje |
| CITADEL ADVISORS LLC | $15 822 054 | 290 100 | 0,37% | Opcja sprzedaży |
| Squarepoint Ops LLC | $15 641 472 | 286 789 | 0,36% | Akcje |
| Jump Financial, LLC | $15 159 502 | 277 952 | 0,35% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $15 034 803 | 275 375 | 0,35% | Akcje |
| GOLDMAN SACHS GROUP INC | $14 855 182 | 272 372 | 0,35% | Akcje |
| NORGES BANK | $14 767 032 | 270 756 | 0,34% | Akcje |
| WELLS FARGO & COMPANY/MN | $14 353 246 | 263 169 | 0,33% | Akcje |
| CITADEL ADVISORS LLC | $13 973 148 | 256 200 | 0,33% | Opcja kupna |
| AMERIPRISE FINANCIAL INC | $13 669 977 | 250 614 | 0,32% | Akcje |
| Vestmark Advisory Solutions, Inc. | $13 213 188 | 242 266 | 0,31% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $12 652 626 | 231 988 | 0,29% | Akcje |
| JANE STREET GROUP, LLC | $12 566 016 | 230 400 | 0,29% | Opcja kupna |
| PEAK6 LLC | $11 633 382 | 213 300 | 0,27% | Opcja sprzedaży |
| Nuveen, LLC | $11 076 474 | 203 089 | 0,26% | Akcje |
| ROYAL BANK OF CANADA | $9 438 000 | 173 045 | 0,22% | Akcje |
| Marex Group Ltd | $9 303 652 | 170 584 | 0,22% | Akcje |
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 zgłoszenia | 16 lutego 2021 | · | Pierwotne zgłoszenie | · | SEC |
| GlaxoSmithKline plc ×5 zgłoszenia | 10 lipca 2020 | · | Pierwotne zgłoszenie | · | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 zgłoszenia | 4 lutego 2020 | · | Pierwotne zgłoszenie | · | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 zgłoszenia | 7 czerwca 2019 | · | Pierwotne zgłoszenie | · | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 zgłoszenia | 8 lutego 2018 | · | Pierwotne zgłoszenie | · | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 zgłoszenia | 16 stycznia 2018 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 32 insiderów · 12 dyrektorzy generalni · 16 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 marca 2026 M | 255 501 | 0 | 9 | $-10 756 932 |
| Brendan Smith | Chief Financial Officer | 18 lutego 2023 M | 5 072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 marca 2021 M | 1 891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 marca 2025 M | 10 544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 sierpnia 2022 A | 26 797 | 0 | 0 | $0 |
| James R. Kasinger | General Counsel and Secretary | 22 września 2026 M | 94 784 | 0 | 6 | $-1 272 398 |
| Naimish Patel | Chief Medical Officer | 29 maja 2026 A | 19 357 | 1 | 2 | $-312 892 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 października 2023 A | 4 411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 grudnia 2021 M | 52 364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 stycznia 2018 M | 25 204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 czerwca 2017 A | · | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 października 2016 C | 505 617 | 0 | 0 | $0 |
| Ali Behbahani | Dyrektor | 17 września 2026 M | 16 637 | 0 | 1 | $-780 934 |
| Christian Rommel | Dyrektor | 5 czerwca 2026 A | · | 0 | 0 | $0 |
| Harold Edward Fleming | Dyrektor | 5 czerwca 2026 A | · | 0 | 0 | $0 |
| Douglas A Treco | Dyrektor | 5 czerwca 2026 A | 22 000 | 0 | 0 | $0 |
| Briggs Morrison | Dyrektor | 5 czerwca 2026 A | · | 0 | 0 | $0 |
| Katherine A High | Dyrektor | 5 czerwca 2026 A | · | 0 | 0 | $0 |
| John Greene | Dyrektor | 5 czerwca 2026 A | 7 000 | 0 | 0 | $0 |
| Simeon George | Dyrektor | 5 czerwca 2026 A | 1 730 179 | 0 | 0 | $0 |
| Maria Fardis | Dyrektor | 5 czerwca 2026 A | · | 0 | 0 | $0 |
| Sandesh Mahatme | Dyrektor | 5 czerwca 2026 A | · | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Dyrektor | 9 czerwca 2022 A | 148 831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Dyrektor | 19 listopada 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Dyrektor | 18 grudnia 2018 S | 1 171 268 | 0 | 0 | $0 |
| Thomas Woiwode | Dyrektor | 15 czerwca 2018 A | 640 014 | 0 | 0 | $0 |
| Anthony N Coles | Dyrektor | 31 maja 2017 A | 70 000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Posiadacz 10% | 4 grudnia 2017 S | 3 722 534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Posiadacz 10% | 24 października 2016 C | 744 380 | 0 | 0 | $0 |
| GSK plc | Posiadacz 10% | 24 października 2016 C | 3 220 627 | 0 | 0 | $0 |
| Raju Prasad | · | 7 sierpnia 2026 G | 14 815 | 0 | 10 | $-5 100 841 |
| Rodger Novak | · | 30 czerwca 2021 S | 573 007 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 27 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,53% | 22 018 NS | 31 lipca 2026 | N-PORT |
| IDNA · iShares Trust | 1,46% | 71 206 SH | 11 września 2026 | Dziennie |
| LABU · Direxion Shares ETF Trust | 0,66% | 68 253 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 6 830 SH | 1 października 2026 | Dziennie |
| IBB · iShares Trust | 0,35% | 685 566 SH | 11 września 2026 | Dziennie |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70 696 SH | 19 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,16% | 2 381 008 SH | 11 września 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536 446 SH | 19 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,14% | 44 639 NS | 31 lipca 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,11% | 6 860 SH | 1 października 2026 | Dziennie |
| ESML · iShares Trust | 0,06% | 34 534 SH | 11 września 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1 106 455 SH | 19 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,04% | 5 543 SH | 11 września 2026 | Dziennie |
| IWO · iShares Trust | 0,04% | 115 267 SH | 11 września 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13 170 SH | 19 sierpnia 2026 | Dziennie |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 1 727 SH | 1 października 2026 | Dziennie |
| XT · iShares Trust | 0,03% | 21 859 SH | 11 września 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7 774 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20 627 SH | 19 sierpnia 2026 | Dziennie |
| IYY · iShares Trust | 0,01% | 4 231 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,01% | 128 500 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,01% | 25 737 SH | 11 września 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75 392 SH | 19 sierpnia 2026 | Dziennie |
| IWN · iShares Trust | · | 760 375 SH | 11 września 2026 | Dziennie |
| ISCB · iShares Trust | · | 4 191 SH | 11 września 2026 | Dziennie |
| ISCV · iShares Trust | · | 20 690 SH | 11 września 2026 | Dziennie |
| SMLF · iShares Trust | · | 58 519 SH | 11 września 2026 | Dziennie |
CRSP Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 28 analityków
KUP
Średni cel
$80.00
+44,3%
6 21,4%
Mocne kupno
11 39,3%
Kup
11 39,3%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
18 analityków · 2026-10-03Średnia cel $87.56 +58,0%
Teraz
Aktualna cena $55.43
Niski$44.00
Średnia$87.56
Wysoki$291.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
Nasdaq · 3 tygodnie, 1 dzień temu
Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
Yahoo Finance · 2 miesiące, 2 tygodnie temu
2 Beaten-Down Stocks With Massive Upside Potential
Nasdaq · 2 miesiące, 3 tygodnie temu
CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
Yahoo Finance · 3 miesiące, 3 tygodnie temu
Akcje CRISPR Therapeutics są absurdalnie tanie – oto dlaczego analitycy widzą 437% potencjału wzrostu
Nasdaq · 3 miesiące, 4 tygodnie temu
Przywództwo Wzrostu Mega-Kapitalizacji czy Potencjał Wzrostu Małych Spółek? VUG vs VBK
Nasdaq · 4 miesiące temu
1 Najwyższy analityk Wall Street uważa, że CRISPR Therapeutics może podwoić swoją wartość. Czy powinieneś kupować akcje bez opamiętania?
Yahoo Finance · 4 miesiące, 2 tygodnie temu
Wykryto znaczący odpływ z ETF - ARKK, CRSP, TEM, HOOD
Nasdaq · 5 miesięcy, 2 tygodnie temu
Ten Biofarmaceutyczna Firma Ma Potencjał, Aby Zdefiniować Na Nowo Cały Obszar Terapeutyczny
Nasdaq · 5 miesięcy, 3 tygodnie temu
Cathie Wood Poluje na Okazje: 2 Akcje, Które Właśnie Kupowała
Nasdaq · 5 miesięcy, 3 tygodnie temu
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 3, 2026